April 27th, 2011
Large Meta-Analysis Finds No Link Between ARBs and MI Risk
Angiotensin-receptor blockers (ARBs) don’t increase the risk for MI, according to a large new meta-analysis published in BMJ. Concerns about ARBs and MI have lingered since the VALUE trial in 2004 found a 19% increase in the risk for MI, though subsequent trials have not reinforced the finding.
Sripal Bangalore and colleagues combined data from 37 randomized trials including more than 147,000 patients and found no increase in MI risk associated with ARBs when compared with controls (relative risk 0.99, CI 0.92-1.07). The authors wrote that the study provides “firm evidence to refute the hypothesis that angiotensin receptor blockers increase the risk of myocardial infarction (ruling out even a 0.3% absolute increase).” Increases in death or cardiovascular death were similarly ruled out. Furthermore, the researchers found that ARBs were associated with significant reductions in the risks for stroke, heart failure, and diabetes.